Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

• Status: Completed
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Ferric Compounds

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• On peritoneal dialysis at least 3 months with a Kt/V of ≥ 1.7

• Use of Automated Peritoneal Dialysis

• Serum phosphate > 5.5 mg/dL or <5.5 mg/dL on a binder other than velphoro

• Serum albumin ≤ 3.7 g/dL

• Able to provide consent

• Ability to complete self-reported questionnaire

Exclusion Criteria:

• Inadequate dialysis

• Current use of sucroferric oxyhydroxide

• Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 6 months

• Active malignancy

• Recent episode of peritonitis

• Pregnancy or planning to become pregnant

• Anticipated kidney transplantation within 6 months

• Factors judged to limit adherence to interventions

• Known adverse side effect to sucroferric oxydroxide